PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gasthepLink to Publisher's site
 
Gastroenterol Hepatol (N Y). 2010 May; 6(5): 326–328.
PMCID: PMC2886495

Hepatitis C Virus Therapy-related Skin Manifestations

Hepatitis C virus (HCV) infection is a significant global health problem. The World Health Organization estimates that approximately 130–170 million individuals worldwide and 1–2.5% of the US population are chronically infected with HCV.1 Patients with HCV are at risk for significant complications such as the development of cirrhosis and hepatocellular carcinoma (HCC). Due to the high prevalence of HCV liver disease, HCV is the leading indication for liver transplantation worldwide.

Because of the high morbidity and mortality associated with HCV infection, attempts should be made to eradicate the virus. Standard treatment of HCV consists of combined pegylated interferon (either alfa-2a or -2b) and ribavirin, with the primary goal of achieving sustained virologic response (SVR). SVR reduces the risk of HCV-infected patients developing fibrosis and progressing to cirrhosis, lowers the risk of HCC, and improves overall liver-related mortality and morbidity.2-6

SVR rates range from 20% to 80%, depending upon factors such as HCV genotype, baseline viral load, presence of advanced fibrosis, insulin resistance, and ethnicity.2-6 SVR is also influenced by the length of treatment (usually 48 weeks for genotypes 1 and 4, and 24 weeks for genotypes 2 and 3),7 dosing,8,9 and patient compliance. McHutchison and associates10 demonstrated that SVR is significantly impacted by adherence to therapy. HCV genotype 1 patients who received at least 80% of their pegylated interferon and ribavirin for at least 80% of the expected duration of therapy experienced a significant difference in SVR compared to those with less than 80% of dosing (63% vs 34%; P=.008). Therefore, treatment adherence at the recommended therapeutic dosages is essential in order to achieve SVR.

However, pegylated interferon and ribavirin are associated with many side effects that can impact patient compliance, dosing, and subsequent SVR. Pegylated interferon is associated with myalgias, arthralgias, fever, fatigue, nausea, diarrhea, headaches, neutropenia, depression, and rash. Ribavirin is associated with hemolytic anemia, nausea, insomnia, and rash. Veluru and colleagues11 describe 3 patients with chronic HCV infection who developed what were likely ribavirin-related skin eruptions during antiviral treatment. All 3 patients developed severe inflammatory skin lesions, which were occasionally pruritic, and all required ribavirin cessation. After a brief drug holiday, the skin manifestations of all 3 patients resolved, and antiviral therapy was restarted.

Because both HCV infection and therapy are associated with cutaneous manifestations, it may be difficult to differentiate between HCV-related and therapy-related skin changes. Up to 38% of HCV-infected patients experience extrahepatic manifestations,12 and up to 17% are dermatologic.13 These conditions include prurigo nodules, purpura secondary to mixed cryoglobulinemia, porphyria cutanea tarda, and lichen planus. Most dermatologic findings related to HCV infection are treated with antiviral therapy, along with supplemental topical treatments.14

Adverse cutaneous reactions are common but are typically treatable complications of HCV combination therapy. Physicians should be aware of these findings and prepared to treat them. Cutaneous side effects associated with interferon and ribavirin treatment are heterogeneous and typically mild, though severe reactions can occur on very rare occasions. Interferon has an overall incidence of cutaneous eruptions of 13–23%.15 The cutaneous side-effect profile of interferon includes transient alopecia, vasculitis, cutaneous necrosis, lichen planus, psoriasis,16,17and, most commonly, injection-site reaction, which is seen in up to 60% of patients.18 Severe skin reactions (including vesiculobullous eruptions, erythema multiforme, and generalized exfoliative dermatitis or erythroderma) have rarely been reported in patients treated with peginterferon alfa-2a alone or in combination with ribavirin.19,20Stevens-Johnson syndrome and toxic epidermal necrolysis have not been reported.20 Oral ribavirin in combination with peginterferon alfa-2a, peginterferon alfa-2b, or interferon alfa-2b has been associated with alopecia, pruritus, dermatitis (in over 20% of patients), dry skin, increased sweating, and generalized morbilliform rash. The majority of HCV treatment-associated rashes are thought to be caused by ribavirin based upon the sharp increase in incidence when ribavirin was introduced to the interferon-based regimens.21 On the other hand, the substitution of interferon with its pegylated form did not lead to an increased incidence of adverse skin effects.9

Morbilliform eruptions are generally the most common adverse drug reactions. These rashes tend to be fine, red, petechial, reticular, and most commonly seen on the arms and trunk, though they can be seen diffusely in more severe cases. The lesions start as erythematous macules that can become palpable in a symmetric distribution, typically starting on the trunk and spreading to the extremities. Mucous membranes are generally spared. Classically, in morbilliform eruptions, the underlying mechanism is thought to be immunologic and is considered a cell-mediated type IV hypersensitivity reaction, though the mechanism is likely more complex and varies depending upon the offending drug. The exact pathophysiology of drug eruptions associated with ribavirin has yet to be elucidated. The cutaneous reaction typically begins 7–14 days after a drug has been started but can be seen later.22Patients treated with combination HCV therapy become more reactive to allergens while on therapy, and enhancement of a T-helper-1-type profile has been seen.23 It has been suggested that histamines may be closely associated with the rash due to ribavirin, but additional studies are necessary to confirm this hypothesis.

Initial evaluation of a patient with a cutaneous side effect from HCV treatment should include a full skin examination in order to exclude rare but serious or life-threatening reactions. Clinical features suggestive of a serious reaction include edema of the face, peripheral hypereosinophilia, blistering, mucous membrane lesions, and intensely painful or dusky skin lesions. Treatment should provide patient comfort and symptom control. Topical application of class III corticosteroids (ie, clobetasone butyrate or triamcinolone acetonide cream or ointment) is generally sufficient for topical therapy. Weaker topical steroids (ie, hydrocortisone) may provide relief in mild cases. Systemic steroids should be avoided due to the risk of altering hepatitis C viral loads.24 Patients should be instructed to apply daily baseline thick emollients and to avoid harsh soaps and any other irritating topical therapies. Treatment with oral antihistamines for symptomatic relief from itching can be added. Reasonable regimens include a morning low-sedation or second-generation H1 antihistamine (ie, loratadine, cetirizine, or fexofenadine) and an evening first-generation H1 antihistamine (ie, hydroxyzine or diphenhydramine hydrochloride).

Most patients with HCV treatment-associated drug reactions may continue their combination therapy without interruption, if appropriate skin treatment is instituted. Treating through (ie, continuing the drug despite a cutaneous eruption in the case of a ribavirin-induced rash) can consist of decreasing the dose of ribavirin, temporarily discontinuing the treatment, or continuing the therapy at full dose and symptomatically controlling the disease. Although there is a paucity of controlled studies to determine the utility of decreasing the dose or stopping ribavirin due to cutaneous side effects, in general, most patients with drug eruptions will see the eruptions disappear even though the drug is continued at full dose. The plasma half-life of ribavirin is 30–40 hours after just 1 dose, whereas at steady state, the half-life is 200–300 hours.25 Therefore, stopping the drug for very short periods of time provides only a small decrease in plasma concentration of the medication. When comparing randomized controlled studies in different HCV treatment regimens, a lower ribavirin dose had a minimal effect on the incidence of rash as an adverse event. In a study of 511 patients treated with peginterferon alfa-2b and ribavirin 800 mg daily, 24% experienced rash associated with treatment.26 Another study found that among patients treated with peginterferon alfa-2b weekly and ribavirin 1,000–1,200 mg daily (228 patients), 28% experienced dermatitis or rash associated with treatment.21 Some morbilliform lesions and early erythema multiforme lesions have similar appearances and can be easily confused; therefore, cutaneous lesions should be monitored if therapy is to be continued to ensure that these lesions do not become more serious.

HCV infection remains an important global burden, and treatment clearly demonstrates a benefit in liver-related morbidity and mortality. It is crucial to emphasize that treatment with pegylated interferon and ribavirin should be continued for the entire duration, as much as can be tolerated. Significant dose reductions (>20% of the targeted dose),7,10 as well as prolonged discontinuation, can lead to significantly lower SVR rates (53% vs 68%; P=.004) and higher relapse rates after treatment (42% vs 29%; P=.02).8 Other trials have also stressed the importance of the continuation of both drugs without interruptions in order to maximize the chance of achieving SVR.8,10,27 Combination therapy remains the standard of care for HCV treatment, and ribavirin continuation at maximal dosing does appear to provide a greater chance of achieving early/rapid viral response and preventing relapse.10

Although the mechanism of ribavirin is not completely understood, it is known that ribavirin provides moderate antiviral effects that can sustain SVR at a higher rate than interferons alone.21,28 Proposed mechanisms of action include depleting guanosine triphosphate levels through inhibition of the enzyme inosine monophosphate dehydrogenase, as well as hindering the HCV RNA-dependent polymerase.8,29 Viral kinetics from ribavirin have been investigated, and it has been demonstrated that viral inhibition is immediate during the first several days of administration, though it can be quickly reversible.30 Studies have also revealed that ribavirin can also enhance the clearance of infected cells and play a key role in the prevention of later-phase HCV replication, which is thought to be the reasoning for post-treatment relapses.31 In addition, immunomodulating effects have been studied, revealing a ribavirin-induced activation of T-helper response among T-helper 1 cells, thus increasing intracellular response toward infected cell clearance.32

Given ribavirin's biological and clinical importance in maintaining antiviral activity, treatment with ribavirin should ideally continue throughout the entire duration of HCV treatment at therapeutic doses. Physicians should be familiar with the rashes associated with HCV treatment and their management, as well as the importance of minimizing HCV treatment interruption. In doing so, SVR rates are maximized, leading to a reduction in liver-related morbidity and mortality.

References

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(suppl 1):74–81. [PubMed]
2. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288. [PubMed]
3. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684. [PubMed]
4. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2008;27:542–551. [PubMed]
5. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313. [PubMed]
6. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997;26:780–785. [PubMed]
7. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355. [PubMed]
8. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040–1048. [PubMed]
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. [PubMed]
10. McHutchison JG, Manns M, Patel K, et al. Adherence to combinationtherapy enhances sustained response in genotype-1-infected patients with chronichepatitis C. Gastroenterology. 2002;123:1061–1069. [PubMed]
11. Veluru C, Atluri D, Chadalavada R, Burns E, Mullen KD. Skin rash during chronic hepatitis C therapy. Gastroenterol Hepatol. 2010;6:323–325. [PMC free article] [PubMed]
12. Chung CM, Nunley JR. Overview of hepatitis C and skin. Dermatol Nurs. 2006;18:425–430. [PubMed]
13. Pearlman BL, Hepatitis C. nfection: a clinical review. South Med J. 2004; 97:365–373.
14. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611–636. [PubMed]
15. Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N. Eczemalike lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150:1046–1047. author reply 1047. [PubMed]
16. Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs. 2000;4:164–168. [PubMed]
17. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005;22:519–528. [PubMed]
18. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237–S244. [PubMed]
19. Gallelli L, Ferraro M, Mauro GF, De Sarro G. Generalized exfoliative dermatitis induced by interferon alfa. Ann Pharmacother. 2004;38:2173–2174. [PubMed]
20. Litt JZ. Drug Eruption Reference Manual. 11th ed. Abingdon, UK: Taylor and Francis Group; 2005. Ribavirin; p. 451.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492. [PubMed]
22. Bolognia JL, Jorizzo JL, Rapini R. Dermatology. Spain: Mosby-Elseiver; 2008. Urticarias, erythemas, and purpuras; p. 304.
23. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153:1088–1090. [PubMed]
24. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253–261. [PubMed]
25. Hardman JG, Limbird LE. Gilbert and Goodman's The Pharmacologic Basis of Therapeutics. 10th Ed. New York, New York: McGraw-Hill; 2001. Antimicrobial agents: antiviral agents; pp. 1336–1337.
26. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965. [PubMed]
27. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–458. [PubMed]
28. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–1499. [PubMed]
29. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002–1009. [PubMed]
30. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin inchronic hepatitis C. Gastroenterology. 2004;126:703–714. [PubMed]
31. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin onhepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–1358. [PubMed]
32. Hultgren C, Milich DR, Weiland O, Sällberg M. The antiviral compoundribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and Cvirus-specific immune responses. J Gen Virol. 1998;79:2381–2391. [PubMed]

Articles from Gastroenterology & Hepatology are provided here courtesy of Millenium Medical Publishing